Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption

Who May Qualify: 1. Patients diagnosed with episodic or chronic migraine according to criteria of the International Classification of Headache Disorders, 3rd Edition. 2. Patients who previously received treatment with a monoclonal antibody (mABs) against CGRP or its receptor at the discretion of their usual neurologist, according to the standard of care and local guidelines. 3. Patients who experienced a positive therapeutic response to mAbs. 4. Patients that received the treatment for a minimum of 3 months. 5. Age between 18 and 65 years. 6. Participants must be capable to describe his/her clinical situation and the characteristics of his/her headache. 7. Participants must have signed the willing to sign a consent form and have sufficient understanding of Spanish language. Who Should NOT Join This Trial: 1. Presence of another type of concomitant chronic headache, defined by frequency greater than 15 days per month in the previous three months, except for medication overuse headache. 2. Patients planning to start another treatment with a possible preventive effect according to the national clinical practice guidelines within the six following weeks after their inclusion in the present study for any therapeutic indication. 3. Patients who started another treatment with a possible preventive effect according to the national clinical practice guidelines within the previous six weeks of the evaluation of the inclusion in the present study. 4. Pregnancy or breastfeeding. 5. Patients who discontinued treatment with the monoclonal antibody due to an adverse effect and not to an efficacy response. Always talk to your doctor about whether this trial is right for you.